Table 1.
Clinical and molecular characteristics of two clusters obtained after NMF analysis using obesity and lipid metabolism gene expression data from TCGA
| NMF Clustering by Obesity‐related Genes | P‐value | ||
|---|---|---|---|
| Cluster 1 | Cluster 2 | ||
| n | 186 | 352 | |
| Age (years) | 58.8 ± 11.2 | 59.9 ± 11.8 | NS |
| Stage | 0.02 | ||
| I | 2 (1.1%) | 14 (4%) | NS |
| II | 7 (3.8%) | 19 (5.4%) | |
| III | 137 (73.7%) | 275 (78.1%) | 0.03 |
| IV | 36 (19.4%) | 41 (11.57%) | |
| NA | 4 (2.2%) | 3 (0.9%) | |
| Mutation count | 49.5 ± 2.5 | 48.1 ± 2 | NS |
| Copy number alterations | 0.49 ± 0.18 | 0.59 ± 0.18 | <0.0001 |
| Histological grade | |||
| G1 | 0 (0%) | 4 (1.2%) | NS |
| G2 | 26 (14%) | 41 (11.8%) | |
| G3 | 156 (83.9%) | 296 (84.8%) | |
| Gx | 3 (1.6%) | 5 (1.4%) | |
| NA | 1 (0.5%) | 3 (0.9%) | |
| Primary diagnosis | |||
| Tumour resection | 143 (76.9%) | 287 (81.5%) | NS |
| Fine needle aspiration biopsy | 4 (2.2%) | 6 (1.7%) | |
| Cytology (e.g. Peritoneal or pleural fluid) | 27 (14.5%) | 44 (12.5%) | |
| Incisional Biopsy | 5 (2.7%) | 7 (2%) | |
| Excisional Biopsy | 4 (2.2%) | 1 (0.3%) | |
| Other methods | 0 (0%) | 1 (0.3%) | |
| NA | 3 (1.6%) | 6 (1.7%) | |
| Residual disease after surgery | |||
| No macroscopic disease | 16 (8.6%) | 87 (24.7%) | <0.0001 |
| 1–10 mm | 96 (51.6%) | 134 (38.1%) | |
| 11–20 mm | 14 (7.5%) | 19 (5.4%) | |
| >20 mm | 38 (20.4%) | 61 (17.3%) | |
| NA | 22 (11.8%) | 51 (14.5%) | |
| Primary optimal debulking (<1 cm) | 112 (60.2%) | 221 (62.8%) | NS |
| Chemotherapy (Chemo) | |||
| Adjuvant | 115 (61.8%) | 235 (73.9%) | NS |
| Progression | 27 (14.5%) | 30 (9.4%) | |
| Recurrence | 22 (11.8%) | 47 (14.8%) | |
| Other | 2 (1.1%) | 6 (1.9%) | |
| NA | 20 (10.8%) | 35 (10%) | |
| ≥three rescue chemo lines | 17 (10.2%) | 30 (9.5%) | NS |
| Primary therapy result | |||
| Complete remission/response | 93 (50%) | 203 (57.8%) | 0.002 |
| Partial remission/response | 33 (17.7%) | 27 (7.7%) | |
| Stable disease | 11 (5.9%) | 16 (4.6%) | |
| Progressive disease | 16 (8.6%) | 19 (5.4%) | |
| NA | 33 (17.7%) | 86 (24.5%) | |
| Disease Status | |||
| Disease‐Free | 32 (17.2%) | 96 (27.3%) | 0.008 |
| Recurred/progressed | 116 (62.4%) | 210 (59.7%) | |
| NA | 38 (20.4%) | 46 (13.1%) | |